Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Genetic factors play a critical role in prostate cancer treatment planning, with both germline and somatic mutations guiding therapeutic decisions. The Association of Cancer Care Centers (ACCC) remains committed to improving prostate cancer care and has developed the Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing. In this episode, CANCER BUZZ speaks with Andrea Murphy, FNP-C, ACGN, CGRA, genetics nurse practitioner at Mary Bird Perkins Cancer Center and Amy D. Smith, FNP-BC, director at Meredith & Jeannie Ray Cancer Center, about the impact this handbook has had on patient care delivery, measuring success during the pilot program, and recommendations for sustaining germline and somatic mutation testing in clinical practice.
“I think a lot of people were surprised, definitely with germline testing, that all metastatic patients met the criteria [for testing]…” – Andrea (Ani) Murphy, FNP-C, ACGN, CGRA
“The other thing that the [hand]book did is [give] us a good outline on what our deficiencies were, where we wanted to go with testing...and just pretty much set it up so that it was easy for us to follow.” – Amy D. Smith, NP-BC
“Overall, I think the handbook could give anybody the guidance that they need to set up their own program.” – Amy D. Smith, NP-BC
Guests:
Andrea (Ani) Murphy, FNP-C, ACGN, CGRA
Nurse Practitioner – Genetics
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Amy D. Smith, FNP-BC
Director
Meredith & Jeannie Ray Cancer Center
Ivinson Memorial Hospital
Laramie, Wyoming
Resources:
Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
